Navigation Links
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
Date:8/18/2010

ent populations and an independent Data Safety Monitoring Board recommended continuation of QPI-1002 clinical development in both diseases. QPI-1002 was granted Orphan designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the prophylaxis of delayed graft function in kidney transplant patients.

About Quark Pharmaceuticals, Inc.Quark Pharmaceuticals, Inc., a world leader in novel RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry. The Company's fully integrated drug development platform spans therapeutic target identification to drug development.  Quark's approach to delivery allows targeting of tissues and organs including the eye, kidney, ear, lung, spinal cord and brain.

In addition to QPI-1002, Quark's pipeline includes PF-655, currently in two Phase II clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The siRNA therapeutic candidate PF-655 is licensed to Pfizer, who is conducting both trials in collaboration with Quark. PF-655 targets Quark's proprietary gene, RTP801, discovered using its BiFAR™ target discovery platform that identifies clinically relevant critical genes and proteins that reverse the disease phenotype when inhibited. The Company owns a family of patents covering the RTP801 gene, its RNA and protein product sequences, specific antibodies, and gene inhibition across different pathologies. For the structure of these products, Quark has obtained licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

Quark is currently conducting clinical trials of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection. QPI-1007 utilizes a proprietary structure developed in collaboration with BioSpring GmbH that provides Quark with freedom to operate in the siRNA intellectual property arena and chemical modifications that are designed to pr
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... FRANKFORT, Ky., Oct. 7, 2011 The Consumer ... the Kentucky General Assembly to adopt a new ... and abuse, the Meth Offender Registry Block List. ... from purchasing medicines containing pseudoephedrine (PSE) –medicines like ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed ... an Abbreviated New Drug Application (ANDA) with the U.S. ... Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 ... mg, and 100 mg/4 mg.  Watson,s Morphine Sulfate and ...
Cached Medicine Technology:Consumer Group Advances Alternative to Prescription Mandate 2Consumer Group Advances Alternative to Prescription Mandate 3Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, ... gathered with US Marines on November 14, 2014 for ... the Toys for Tots Literacy Program. This year’s ... books and audio books for the Toys for Tots ... Christmas. It represents another major strike in the battle ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... Verde Pointe Dental Associates 2014 Ugly Holiday ... years homemade Christmas sweater lit up, but this years overall ... is Tandy Wilson for the second year in a row. ... Kimmerling DDS. "She took pictures of the entire staff and ... , "Every year I enjoy stopping by the dental ...
(Date:12/24/2014)... Dental implants benefit millions of individuals ... They offer the strongest and most secure hold for ... of tooth replacement. They will never slip out of ... for support, and they prevent the jaw from shrinking ... they are not suitable candidates for dental implants because ...
(Date:12/24/2014)... 24, 2014 Attorneys handling talcum powder ... update to their website, the Talcum Powder Ovarian ... talcum powder class action lawsuits and ovarian cancer claims. ... ovarian cancer updates at their website, which serves as ... ovarian cancer claims are not the same as class ...
Breaking Medicine News(10 mins):Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... University of Texas, offer some valuable advice on how to ... essential for healthy bones and teeth, and helps prevent osteoporosis ... helps the body produce vitamin D.// Just10 to 15 minutes ... But be warned many factors can reduce sunlight exposure, such ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
... study, a combined scan identifies unstable areas of plaque in ... the future. Fatty deposits, known as plaque, set the scene ... - begins many years before any symptoms occur.// The plaque ... a clot which will then cause a heart attack. ...
... recent study by researchers at the University of Texas, have ... cancer.Omega-3 fatty acids, which are found in fish oil, have ... that the omega-3s block a molecule called protein kinase C ... division. ,In this study, genetically-modified mice, which produce ...
... suggested by researchers to relieve chronic headaches. Botox injections ... not relieved by conventional medication. Botox is shorthand for ... to man. However, it does have some benign uses ... out wrinkles in cosmetic surgery. Now researchers at the ...
Cached Medicine News:
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
2 mm wide curved tip. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Medicine Products: